Vaccinia Viral Vector Development Service
Vaccinia viruses are widely used as tools for gene transfer and to enable high levels of cytoplasmic expression of transgenes. Our company is committed to providing services for the development of highly attenuated, non-replicating, or poorly replicating vaccinia virus vectors for rare disease gene therapies to meet the diverse gene delivery needs of our customers in gene therapy development.
Background
Most types of cancer are considered rare, and they are usually more difficult to diagnose and treat than common cancers because of the small number of cases and the difficulty of research. The advent of gene therapy offers a promising strategy for the treatment of rare cancers, however, the development of in vivo cancer gene therapy is limited by major obstacles such as inefficient gene delivery and expression, lack of specific tumor targeting, and immune clearance. vaccinia viruses have many properties that make them ideal vectors for cancer gene therapy.
Vaccinia viruses have a high transduction efficiency with high levels of gene expression. Unlike most vector systems that rely exclusively on the host transcriptional machinery, gene expression in the vaccinia viruses is not dependent on host cell replication. Vaccinia viruses also have the advantage of a large genome and can easily be cultured at high titers. In addition to this, several groups have reported selective targeting of vaccinia viruses to tumor tissue in vivo. The unique advantages of the vaccinia virus make it a suitable vector for gene therapy, offering hope for the development of new therapies for different rare cancer types.
Fig. 1 Construction of recombinant vaccinia virus vectors by homologous recombination. (Al Ali S, et al., 2016)
Our Services
Our researchers are devoted to improving the safety of vaccinia virus vectors to help customers reduce the risk of cytopathic effects in gene therapy research. Our services include, but are not limited to:
- Gene editing of vaccinia virus
We help customers edit vaccinia viruses with an efficient and flexible CRISPR-Cas9 system to delete viral genes or arm vaccinia viruses with therapeutic genes, thus obtaining marker gene-positive TK mutant vaccinia virus vectors. - Modification of vaccinia virus
We provide modified vaccinia virus, including TK-deleted vaccinia virus, to improve the tumor targeting and oncolytic effect of the virus in gene therapy. Modified vaccinia virus vectors we provide include modified vaccinia Ankara（MVA）vector, NYVAC vector, ALVAC vector, and others vectors. - Construction of new recombinant vaccinia virus vectors
We provide three approaches to help customers create new recombinant vaccinia virus. - The method of homologous recombination takes place inside the cells.
- The method of in vitro ligation of a foreign gene into the vaccinia virus genomic DNA.
- The method of construction of recombinant vaccinia virus vectors by combining high-frequency recombination and replication catalyzed by leprosy virus Shope fibroma virus (SFV) with SFV-promoted reactivations.
Our Solutions
- Construction of vaccinia virus vectors expressing immunoregulatory factors, such as IL-2.
- Construction of vaccinia virus vectors expressing chemokines, such as CXCR3.
- Construction of vaccinia virus vectors expressing apoptosis-inducing genes.
- Construction of vaccinia virus vectors expressing tumor-suppressor genes.
- Construction of vaccinia virus vectors expressing suicide genes, such as FCU1.
Applications
- Development of vaccinia virus vectors for gene transfer in vitro
- Development of vaccinia virus vectors for gene delivery in vivo
Our company has many years of experience and best-in-class technology in the development of gene delivery tools. We are well-placed to provide a one-stop shop for the design and construction of suitable gene delivery vectors for your rare disease gene therapy development project. If you are interested in our services, please feel free to contact us and we look forward to working with you!
Reference
- Al Ali, S.; et al. Use of reporter genes in the generation of vaccinia virus-derived vectors. Viruses, 2016, 8(5): 134.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
